|
Aventis Pharma launches SoloStar in India
2008-05-14 05:25:00 Aventis Pharma Limited, a Sanofi-Aventis group company, has launched a new prefilled disposable insulin pen SoloStar for use with the 24-hour insulin Lantus."The insulin market in India is about Rs 410 crore and we have captured a market of about 7% with Lantus. The launch of SoloStar will boost our market share by another 1-2%," said Susheel Umesh, senior director, Cardio-Metabolism Business Unit who was in Ahmedabad for the launch. The Chicago Athenaeum Museum of Architecture and Design awarded the 2007 Good Design award to SoloStar.Lantus has a global market of 2 billion Euros. SoloStar reduces the injection force by 30% or more in comparison to other leading disposable pens, he added.According to diabetologist Sanjeev Phatak after Tamil Nadu, Gujarat has highest prevalence of diabetes. "There would be 30-40 lakh diabetes patients in Gujarat of which about 4-5 lakh would be in Ahmedabad," Phatak said.Source: business-standard.com
Acomplia by Sanofi-Aventis: Re-Defining Your Body Shape
2008-04-10 22:00:00 Pondering over weight loss? With obesity spreading far and wide, entrapping young and old alike in its ambit, it is important to find a solution to this health hazard. Weight loss pills which have made their presence felt in the recent past, can offer you a solution. Among the enormous list of weight loss pills ...
By: Rimonabant 2007
Generic acomplia Sanofi Aventis
2008-01-22 09:42:00 Generic acomplia Sanofi Aventis Info related to acomplia Sanofi Aventis Generic Acomplia Rimonabant Zimulti available in Market now We now offer Generic Rimonabant Zimulti Acomplia information to users which is available to ship worldwide. See below for more information about Generic Acomplia Rimonabant 20 Mg We also offer Branded Acomplia Rimonabant which is manufactured by Sanofi-Aventis. Rimonabant is sold under ...
Sanofi-Aventis Response To BMJ Article On Obesity Drugs Achieving Modest We
2007-11-19 21:08:00 The British Medical Journal recently published an article stating that most obesity drugs achieve 'modest' weight loss. Below is the response from Sanofi-Aventis. [click link for full article]
Sanofi-Aventis Response To BMJ Article On Obesity Drugs Achieving Modest We
2007-11-19 21:08:00 The British Medical Journal recently published an article stating that most obesity drugs achieve 'modest' weight loss. Below is the response from Sanofi-Aventis. [click link for full article]
Acomplia Sanofi Aventis: Messiah For The Obese
2007-10-08 22:34:00 Acomplia is a Sanofi Aventis creation, which is a large cap French pharmaceutical firm. Weight loss medication Acomplia is a product of two years of clinical trials undertaken in North America. Weight loss is not the only benefit which is sourced by use of this diet pill. Usage of this weight loss medication has also ...
By: Rimonabant 2007
Acomplia online order, aventis sanofi acomplia buy
2007-09-03 07:13:00 Buy Acomplia About 2 in 5 adults you come across in the UK are overweight ? this problem is not only restricted to UK but also affects increasing number of people across the world. Exercises and diets do help, but a weight loss drug is your safest option helping you to get rid of those unwanted ...
Sanofi-Aventis announce the launch of Acomplia in the UAE
2007-08-27 18:44:00 Sanofi-Aventis announced the launch of Acomplia (rimonabant), their new scientific drug for the treatment of abdominally obese patients with cardio metabolic risk cluster. The drug has received approval from the European Medicines Evaluation Agency (EMEA) to be used in combination with diet and exercise for the treatment of abdominal obesity with cardio metabolic risk cluster, and ...
acomplia sanofi aventis - Sanofi-Aventis Acomplia provides long term cardio
2007-08-12 22:46:00 New data shows that Sanofi-Aventis’ developmental drug Acomplia (rimonabant) significantly improved blood sugar levels in trial patients with Type 2 diabetes, while also reducing body weight. The new data comes from Sanofi-Aventis’ first non-obesity trial with Acomplia. The results of the six month trial, dubbed …acomplia sanofi aventis Sanofi-Aventis SA says Acomplia, its new antiobesity drug, ...
Acomplia aventis rimonabant sanofi
2007-08-11 15:45:00 acomplia aventis rimonabant sanofi Top acomplia aventis rimonabant sanofi Resources Our Top acomplia aventis rimonabant sanofi Resource Rimonabant acomplia Best source for rimonabant acomplia, compare prices Click Here Right Now More acomplia aventis rimonabant sanofi Resources Buy Acomplia Rimonabant.com BuyAcompliaRimonabant.com - your discreet interface to order acomplia rimonabant online! Learn about acomplia rimonabant and buy acomplia rimonabant online with complete confidence. Acomplia - Acomplia ...
Sanofi-Aventis announce the launch of Acomplia in the UAE
2007-07-19 03:15:00 Sanofi-Aventis announced the launch of Acomplia (rimonabant), their new scientific drug for the treatment of abdominally obese patients with cardio metabolic risk cluster. The drug has received approval from the European Medicines Evaluation Agency (EMEA) to be used in combination with diet and exercise for the treatment of abdominal obesity with cardio metabolic risk cluster, and ...
Sanofi Aventis Rimonabant
2007-07-08 21:14:00 We offer the lowest prices on all medications. If you find a retail website that offers a less expensive price, we will match their price AND give you an additional 5% off! Now click here and order the wonder pill, to obtain your dream weight. Only one click away!!! 100% proved and guaranteed results! 24/7 ...
Sanofi-Aventis Withdraws New Drug Application for Rimonabant
2007-07-03 19:20:00 Sanofi-aventis announced it would withdraw its new drug application for Zimulti (Rimonabant) after an FDA advisory committee recommended against approving the drug over concerns it increased the risk of suicide. The agency’s Endocrinological and Metabolic Drugs Advisory Committee voted unanimously that available safety data was insufficient to evaluate Zimulti’s (rimonabant) risk profile. The committee held the meeting over concerns of potential safety signals for psychiatric adverse events and suicidality. Sanofi-aventis also said it plans to submit an update of rimonabant’s safety data to the European Medicine’s Agency (EMEA) Committee for Medicinal Products for Human Use. The agency announced it will review data on psychiatric events as part of its continuous monitoring of the drug’s safety. The EMEA announced it would re-examine the drug after the FDA advisory committee voted against its approval. Source: American College of Clinical Pharmacology eNews group dated 3rd ...
Pharmaceutical company Sanofi-Aventis withdraws FDA application for obesity
2007-07-01 17:59:00 The Wall Street Journal reported today that giant European drug manufacturer Sanofi-Avantis officially withdrew from the FDA its application for approval of its obesity drug Zimulti ( Avandia). A few weeks ago an FDA panel of experts had recommended that the FDA not approve Zimulti due to psychiatric risks. These risks included increased depression and suicidal ideations by the study patients in the Phase III clinical trial. The panel said additional safety data were needed before the FDA should consider approving the drug. The drug is on the market in the Europe , but it isn't allowed to be prescribed to patients suffering from depression, because of possible psychological side effects.Sanofi-Aventis SA said it is withdrawing its application to sell the obesity drug rimonabant in the U.S. but plans to resubmit it at a future date, admitting the defeat, for now, of what it had hoped would be a blockbuster medicine.Depression patients are at twice the ri...
Sanofi-Aventis announce the launch of Acomplia in the UAE
2007-06-15 19:36:00 We offer the lowest prices on all medications. If you find a retail website that offers a less expensive price, we will match their price AND give you an additional 5% off! Now click here and order the wonder pill, to obtain your dream weight. Only one click away!!! 100% proved and guaranteed results! 24/7 ...
Sanofi-Aventis (H5N1): le premier vaccin humain contre la grippe aviaire
2007-04-20 05:48:00 (Boursier.com) - Sanofi pasteur, la division vaccins de Sanofi-Aventis, a annoncé ce mardi soir que la Food and Drug Administration américaine (FDA) avait enregistré son vaccin contre le virus H5N1, le 1er vaccin humain contre la grippe aviaire autorisé aux Etats-Unis. La demande d’enregistrement “Biologics License Application” de vaccin H5N1 a été soumise à la FDA ...
By: Tunindex news
Medimmune licenses vaccine technology to sanofi-aventis
2007-03-30 03:03:00 FluMist maker MedImmune says it has licensed its flu vaccine technology to sanofi pasteur, the vaccines division of French drug giant sanofi-aventis Group. (Source: bizjournals.com Health Care:Pharmaceuticals headlines) More: continued here
Job losses at Sanofi - Aventis in Waterford
2007-03-14 22:39:00 Today's news of 200 job losses at the pharmaceutical plant Sanofi-Aventis in Waterford is a devastating blow for an area that has seen more than its fair share of job losses in recent times. Of course at times like this our thoughts must be with those who are losing their jobs. This will be a very difficult time for these workers and their families as they try to come to terms with this news. Every effort must be made by the Government to find replacement industry for Waterford as soon as possible. This is another in a long list of companies to either close their doors permanently or to shed jobs. Companies such as Waterford Crystal, Bausch and Lomb as well as Hasbro have all seen job cuts and now the news of the loss of these 200 jobs in Aventis will further damage the economy in the region. What is important now is that the states job creation agencies provide assistance to those workers in order to help them secure alternative employment in the months ahead. It is time now ...
Sanofi-Aventis Acomplia
2007-03-05 12:00:16 Acomplia is just one drug in Sanofi's portfolio, so it is hardly the ideal way to get pure exposure
By: Acomplia
Sanofi-Aventis Acomplia
1970-01-01 00:59:00 Acomplia is just one drug in Sanofi's portfolio, so it is hardly the ideal way to get pure exposure
By: Acomplia
|
|
 |
|
 |
